Although the Q4 sales numbers came in ahead of the management’s guidance, likely driven by the consumables business, they missed our expectations. No doubt the equipment-led business is taking time to recover due to a slim order pipeline. Given the high-margin nature of the consumables business, the operating margin improved sequentially although it was down yoy possibly due to continued investment in digitalization. Given the current trend of COVID infections, the management expects a slow star ....
30 Oct 2020
Recovery visible in Q4; cautious start guided for FY20/21
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Recovery visible in Q4; cautious start guided for FY20/21
Carl Zeiss Meditec AG (AFX:WBO), 0 | Carl Zeiss Meditec AG (AFX:ETR), 0 | Carl Zeiss Meditec AG (0DHC:LON), 0 | Carl Zeiss Meditec AG (CZMWF:OTC), 0 | Carl Zeiss Meditec AG (AFX:SWX), 0
- Published:
30 Oct 2020 -
Author:
Sumit Sayal -
Pages:
2
Although the Q4 sales numbers came in ahead of the management’s guidance, likely driven by the consumables business, they missed our expectations. No doubt the equipment-led business is taking time to recover due to a slim order pipeline. Given the high-margin nature of the consumables business, the operating margin improved sequentially although it was down yoy possibly due to continued investment in digitalization. Given the current trend of COVID infections, the management expects a slow star ....